#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
This article examines how the endocannabinoid system changes with aging and how these changes affect cannabis response in older adults. As the endocannabinoid system naturally declines with age, affecting cannabinoid receptor density and endogenous cannabinoid production, older patients may experience altered pharmacodynamics and potentially increased sensitivity to cannabis effects. Understanding these age-related physiological changes is critical for clinicians prescribing to geriatric populations, as standard dosing may result in unexpected side effects or therapeutic responses in this vulnerable group. The research highlights that older adults represent a distinct pharmacological population requiring individualized dosing strategies and careful monitoring. For clinical practice, clinicians should recognize that older patients typically require lower cannabis doses and more frequent dose adjustments than younger populations, and should counsel patients about age-specific risks including increased fall risk, cognitive effects, and drug interactions.
“What we’re seeing in clinical practice is that the endocannabinoid system fundamentally changes with age, which means a 70-year-old patient cannot be dosed like a 40-year-old, yet most prescribers still treat cannabis like a one-size-fits-all medication. Understanding this neurobiological reality allows us to titrate more carefully in older adults and actually achieve therapeutic benefit without the adverse effects that have made many of my elderly patients reluctant to try cannabis in the first place.”
? The endocannabinoid system undergoes age-related changes that may explain why older adults often display different pharmacodynamic responses to cannabis compared to younger populations, a clinically important distinction that remains understudied in formal trials. Age-associated alterations in cannabinoid receptor density, endogenous ligand production, and metabolic capacity could affect both therapeutic efficacy and adverse event profiles, yet most cannabis dosing guidance does not account for these physiological shifts. Important confounders include polypharmacy and drug-drug interactions through hepatic metabolism, comorbid conditions affecting endocannabinoid function, and the high heterogeneity of cannabis products available without standardized composition. Given the growing use of cannabis among older adults for pain, sleep, and neuropsychiatric symptoms, clinicians should recognize that “start low and go slow” dosing principles may be particularly warranted in this population, and consider baseline cognitive and
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it:
